NextBigFuture

Six injections a year of Fasenra fixes the root cause of extreme Asthma in many people

Fasenra is an injected medication that helps prevent severe asthma attacks (exacerbations) and may improve your breathing. Fasenra reduces blood eosinophils. About 50% of people with severe asthma ...
Business Wire

FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis

Dr. Michael Wechsler, Professor of Medicine and Director of The Asthma Institute at National Jewish Health, and International Coordinating Investigator of the MANDARA trial said: “This approval is ...
PharmiWeb

Fasenra met the primary endpoint in the MANDARA Phase III trial in eosinophilic granulomatosis with polyangiitis (EGPA)

First head-to-head trial of biologics in EGPA, comparing a single monthly injection of Fasenra to three injections per month of mepolizumab Positive high-level results from the MANDARA Phase III trial ...
PharmiWeb

FASENRA approved for treatment of children aged 6 to 11 with severe asthma - Additional indication for pediatric patients with severe eosinophilic asthma

AstraZeneca’s FASENRA® (benralizumab) is now approved by the US Food and Drug Administration (FDA) for add-on maintenance treatment for patients with severe asthma aged 6 to 11 with an eosinophilic ...
Yahoo Finance

AZN Gets FDA Nod for Fasenra Label Expansion in Rare Disease

AstraZeneca AZN announced that the FDA has approved its marketed asthma drug, Fasenra (benralizumab) for a new indication. The regulatory body has now approved Fasenra for treating adult patients with ...
FiercePharma

AstraZeneca's Fasenra nabs at-home auto-injector nod, matching GlaxoSmithKline's Nucala

In its heated severe asthma fight with AstraZeneca’s Fasenra, GlaxoSmithKline could take solace in the fact that its drug was more convenient for patients, with a self-administered injection option.
Healio

Fasenra receives FDA approval for asthma treatment in children aged 6 to 11 years

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...
PMLiVE

AstraZeneca’s Fasenra approved by EC to treat rare inflammatory disease EGPA

AstraZeneca’s Fasenra (benralizumab) has been approved by the European Commission (EC) to treat eosinophilic granulomatosis with polyangiitis (EGPA), a rare immune-mediated inflammatory disease that ...
Yahoo Finance

AstraZeneca’s Fasenra meets primary endpoint in Phase III rare vasculitis trial

AstraZeneca’s Fasenra (benralizumab) met its primary endpoint in the MANDARA trial by demonstrating non-inferiority to the current standard of care, GSK’s Nucala (mepolizumab), in patients with ...
Medical Xpress

FDA adds Fasenra indication for severe asthma in children

The U.S. Food and Drug Administration has approved an additional indication for AstraZeneca's Fasenra (benralizumab) as an add-on maintenance treatment for patients aged 6 to 11 years with severe ...
Business Wire

FASENRA met the primary endpoint in the MANDARA Phase III trial in eosinophilic granulomatosis with polyangiitis (EGPA)

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the MANDARA Phase III trial showed AstraZeneca’s FASENRA (benralizumab) met the primary endpoint of the trial and demonstrated ...